Alpha 2.0
Login Register
» Authors » Brian Calingaert

Brian Calingaert

Explore the profile of Brian Calingaert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 1385
Followers 0
Related Specialties
Public Health
Oncology
Pharmacology
Top 10 Co-Authors
Andrew Berchuck
Joellen M Schildkraut
Susana Perez-Gutthann
James A Kaye
Patricia G Moorman
Susan Halabi
Jordi Castellsague
Angeles Alvarez Secord
Kenneth J Rothman
Laura J Havrilesky
Published In
Gynecol Oncol
Pharmacoepidemiol Drug Saf
Cancer Epidemiol Biomarkers Prev
Pharmaceut Med
Epidemiology
Affiliations
Soon will be listed here.
Recent Articles
1.
Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis by antipsychotic treatment status in the United States
Rao S, Forns J, Danysh H, Calingaert B, Dempsey C, Aquilina T, et al.
J Alzheimers Dis . 2024 Nov; 102(4):1260-1270. PMID: 39604278
Background: While some literature on clinical outcomes in persons with dementia-related psychosis exists, little is known regarding Alzheimer's disease-related psychosis (ADP). Objective: Describe demographic/clinical characteristics of adults with ADP and...
2.
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study
Anthony M, Aroda V, Parlett L, Djebarri L, Berreghis S, Calingaert B, et al.
Diabetes Care . 2024 Feb; 47(4):712-719. PMID: 38363873
Objective: To assess risk of anaphylaxis among patients with type 2 diabetes mellitus who are initiating therapy with a glucagon-like peptide 1 receptor agonist (GLP-1 RA), with a focus on...
3.
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, et al.
Pharmaceut Med . 2024 Jan; 38(2):145-156. PMID: 38296916
Background: Cyproterone acetate (CPA) is a synthetic progesterone derivative introduced in the 1970s and prescribed as antiandrogenic therapy for inoperable prostate cancer, sexual deviations in men, and signs of androgenization...
4.
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials
Zografos L, Andrews E, Wolin D, Calingaert B, Davenport E, Michel A, et al.
Pharmaceut Med . 2023 Dec; 38(1):63-73. PMID: 38049618
Background: Materials have been distributed in the European Union to inform physicians on the safe use of intravitreal aflibercept (IVT-AFL) as part of the risk-minimization plan for IVT-AFL. Objective: We...
5.
Distribution of gestational age at birth by maternal and infant characteristics in U.S. birth certificate data: Informing gestational age assumptions when clinical estimates are not available
Margulis A, Calingaert B, Kawai A, Rivero-Ferrer E, Anthony M
Pharmacoepidemiol Drug Saf . 2023 Apr; 32(9):1012-1020. PMID: 37067897
Purpose: We aimed to describe the distribution of gestational age at birth (GAB) to inform the estimation of GAB when clinical or obstetric estimates are not available for perinatal pharmacoepidemiology...
6.
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
Danysh H, Johannes C, Beachler D, Layton J, Ziemiecki R, Arana A, et al.
Drug Saf . 2022 Dec; 46(2):175-193. PMID: 36583828
Introduction: At the time of dapagliflozin's approval in Europe (2012) to treat patients with type 2 diabetes mellitus, concerns regarding acute liver injury and severe complications of urinary tract infection...
7.
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
Johannes C, Beachler D, Layton J, Danysh H, Ziemiecki R, Arana A, et al.
Drug Saf . 2022 Dec; 46(2):157-174. PMID: 36528670
Introduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor approved to treat type 2 diabetes mellitus (T2DM), among other conditions. When dapagliflozin was approved in Europe for treating T2DM (2012), potential...
8.
The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database
Johannes C, Saltus C, Kaye J, Calingaert B, Kaplan S, Gordon M, et al.
Pharmacoepidemiol Drug Saf . 2022 Feb; 31(6):643-651. PMID: 35224798
Purpose: Compare the risk of melanoma between initiators of rasagiline or other antiparkinsonian drugs (APDs) in a Parkinson's disease (PD) population. Methods: A retrospective cohort study was conducted in the...
9.
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)
Arana A, Pottegard A, Kuiper J, Booth H, Reutfors J, Calingaert B, et al.
Clin Epidemiol . 2022 Jan; 13:1141-1153. PMID: 35002327
Purpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma...
10.
Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries
Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, et al.
Expert Opin Drug Saf . 2021 Nov; 21(3):435-446. PMID: 34806928
Background: At the request of the European Medicines Agency, a Prescriber Guide and Patient Alert Card were developed to increase awareness and understanding about the initiation of rivaroxaban and potential...